Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6633598 | 0.81 | LMNA (0.37) | ALDH1A1CASP1CASP7HSD17B10TDP1 | |
| SCHEMBL3917232 | 0.79 | LMNA (0.37) | NSD2CASP6ALDH1A1CASP1CASP7 | |
| SCHEMBL9621749 | 0.73 | NT5E (0.43) | NSD2CASP6ALDH1A1HSD17B10TDP1 | |
| SCHEMBL9950648 | 0.72 | CA1 (0.45) | NSD2MMP14CASP6CA1CA2 | |
| SCHEMBL7048605 | 0.71 | CA1 (0.33) | NSD2MMP14CASP6CA1CA2 | |
| SCHEMBL9951728 | 0.70 | CA1 (0.43) | NSD2MMP14CASP6CA1CA2 | |
| SCHEMBL5434170 | 0.70 | CA1 (0.43) | NSD2MMP14CASP6CA1CA2 | |
| SCHEMBL7041141 | 0.70 | ENPP2 (0.48) | CA1CA2ALDH1A1TDP1 | |
| SCHEMBL11337530 | 0.69 | LMNA (0.35) | CASP6CA1CA2ALDH1A1CASP1 | |
| SCHEMBL5077891 | 0.69 | CA1 (0.42) | NSD2MMP14CASP6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0278910-B1 | HEAVY METAL COMPLEX DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1992-01-22 | — | — | EP | claimed |
| US-RE49569-E1 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| EP-2546231-B1 | ALKYLAMINE DERIVATIVE | EA PHARMA CO LTD (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9561216-B2 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9253997-B2 | Alkylamine derivative | AJINOMOTO CO., INC. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-9150505-B2 | Prophylactic or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2015-10-06 | — | — | US | disclosed |
| CN-102781910-B | alkylamine derivatives | AJINOMOTO KK | 2015-03-11 | — | — | CN | disclosed |
| US-20130237702-A1 | ALKYLAMINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20130072491-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2546231-A1 | ALKYLAMINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2543660-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-4960870-A | DYEING WOOL, POLYAMIDES; FIBER REACTIVE DYES | CIBA-GEIGY CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| US-4248771-A | FOR DYEING AND PRINTING | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| US-4150942-A | DYE LEATHER GRAY | SANDOZ LTD. (CH) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072491-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | CASR, GPR119, GLP1R | NSD2 3648/4885MMP14 1635/4885CASP6 1826/4885 |
| US-20160101091-A1 | ALKYLAMINE DERIVATIVE | CASR, TAAR5, TAAR1 | NSD2 1189/4885MMP14 4040/4885CASP6 1829/4885 |
| US-20130237702-A1 | ALKYLAMINE DERIVATIVE | CASR, TAAR5, TAAR1 | NSD2 1189/4885MMP14 4040/4885CASP6 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.